SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Units of beneficial interest

QQQ is trending as market participants weigh heightened geopolitical tensions in the Middle East against a potential relief rally fueled by rumors of diplomatic negotiations in Pakistan. Community sentiment is deeply divided, with traders closely monitoring the Strait of Hormuz, potential shifts in oil supply, and the impact of technical oversold conditions on institutional positioning.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

Market participants are actively debating the impact of volatile geopolitical headlines and contradictory leadership commentary on the escalating conflict in the Middle East, with many traders questioning the reliability of ongoing negotiations and their potential to stabilize energy markets. The conversation is dominated by skepticism regarding policy effectiveness and widespread uncertainty, leading investors to hedge positions while monitoring key technical levels for potential volatility shifts.

TLGY Acquisition Corp. is a blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Jin-Goon Kim in May 2021 and is headquartered in Wilmington, DE.

TLGY Acquisition Corp - Ordinary Shares - Class A

TLGY is generating significant market interest as investors monitor its vertical alignment and strategic business combination to form StablecoinX. Community discussion remains heavily focused on the pivotal role of shared leadership across related entities and the potential impact of these developments on the emerging digital asset and stablecoin treasury landscape.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently garnering significant community attention driven by broader debates over its role in the crypto market cycle and ongoing development of various memecoin projects within its ecosystem. While some investors remain cautious about volatility, others are actively tracking accumulation patterns and long-term utility plays as market participants assess the asset's potential for future growth.

Pelican Acquisition Corporation is a special-purpose acquisition company that aims to merge with or acquire businesses, particularly in the global technology sector. The company's primary purpose of facilitate a merger, share exchange, asset acquisition, share purchase, reorganization, or any other form of business combination with one or more businesses.

Greenland Energy Co.

Greenland Energy Co. is experiencing extreme volatility and intense community interest driven by its recent NASDAQ debut and speculative excitement surrounding potential oil drilling rights in Greenland. Investors are actively debating the company's long-term potential as a major energy player versus concerns about it being a high-risk, thin-float momentum play prone to rapid price swings.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting strong Week 40 Phase 3 clinical trial results, which investors view as a pivotal 'best-in-class' validation that strengthens the case for regulatory approval and potential acquisition interest. While the community is actively debating the stock's intrinsic value versus institutional price suppression, the consensus among long-term holders is that the clinical data effectively mitigates previous regulatory concerns and sets the stage for a significant valuation re-rating.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Magnificent Seven ETF ($MAGS) is a major focus for investors navigating market volatility, as community members debate whether these tech leaders will continue to drive market gains or suffer from an AI bubble, stretched valuations, and shifting macro conditions. Active discussions are heavily split between those viewing the basket as a long-term 'buy-and-hold' play and others warning that broader market rotation and expensive AI capital expenditures suggest a correction is imminent.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is generating buzz as community members highlight its role in the "Agentic Economy," emphasizing the protocol's chain abstraction and recent integrations that enable AI agents to transact autonomously. While some investors express frustration over price action and sentiment, the discourse is heavily focused on long-term utility, with many tracking developments like NEAR Intents and the potential for increased institutional adoption.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending as investors weigh its recent strategic acquisitions in photonics and hardware against broader sector volatility. Community discussions are split between those betting on the long-term potential of the firm's room-temperature technology and those expressing frustration over ongoing price swings and the speculative nature of the quantum sector.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is currently a focal point for investors speculating on energy sector tailwinds as escalating Middle East tensions and potential supply disruptions keep crude oil prices elevated. The community remains deeply divided, with bulls betting on a short squeeze and long-term oil price strength while skeptics highlight concerns regarding the company's fundamentals, recent insider selling, and potential dilution risks.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care

Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care PR Newswire VANCOUVER, BC, March 19, 2026...

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned an average rating of "Hold" from the six brokerages that are currently covering the stock, Marketbeat.com...

TScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut TScan Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

HC Wainwright Issues Positive Outlook for TCRX Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - HC Wainwright raised their Q1 2026 earnings estimates for TScan Therapeutics in a research note issued on Wednesday, March 4th. HC Wainwright...

FY2030 Earnings Estimate for TCRX Issued By HC Wainwright

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 EPS estimates for shares of TScan Therapeutics in a note issued to investors on...

TScan Therapeutics (NASDAQ:TCRX) Price Target Raised to $5.00

Wedbush lifted their price target on TScan Therapeutics from $4.00 to $5.00 and gave the stock an "outperform" rating in a research note on Thursday...

TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate...

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +34.31% and -37.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Breakdown: TScan Therapeutics Q4

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +24.11% and +39.36%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Tscan Therapeutics Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Current Price	$0.9885
Prev Close	$1.03
Open	$1.02
Dividend Yield	0.00%
50-Day Moving Average	$1.06
Beta	1.23
Avg. Volume	461,574.98
PE Ratio	-0.99

52-Week High	$2.57
52-Week Low	$0.8824
Market Capitalization	$56.25M
EPS (Annual)	-$0.9999
Price to Book	0.46
Revenue Per Employee	$72,711.27

TCRX
Tscan Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TCRX News

TCRXTscan Therapeutics Inc